Abstract Unresectable, metastatic, recurrent gastrointestinal stromal tumor (GIST) is primarily treated with a molecular-targeted therapeutic agent, imatinib. However, after an initial response, a secondary resistance to the drug often occurs after a few years. We report here a case of a resected giant GIST of the jejunum that disseminated following treatment with imatinib. A 59-year-old male presented with a giant tumor in the abdominal cavity, which was diagnosed as GIST by needle biopsy; he was administered 400 mg/day imatinib. Eight months later, the tumor had considerably decreased, but multiple tumors in the small intestine and mesenterium, indicating dissemination, appeared. Administration of imatinib was continued, and the dissemination gradually reduced and almost disappeared except for a tumor in the right upper abdomen. Three years later, follow-up computed tomography revealed that the disseminated lesions had enlarged; a part of the intrapelvic tumor was suspected to be viable. We deduced that the tumor developed partial resistance to imatinib: therefore, we surgically removed as many disseminated tumors as possible. Pathologically, resected tumors appeared to have no viable tumor cells except for a small part of the primary tumor in which mitosis was 0-1/50 high-power fields. Genetic analysis of c-Kit mutation revealed an exon 11 c554-559 deletion. The patient remained recurrence-free for 10 months after surgery. When partial resistance to imatinib is observed, combined modality therapy that involves chemotherapy with surgical intervention at early stages is expected to improve the outcome.
Introduction
Gastrointestinal stromal tumors (GIST) are specific, generally Kit (CD117)-positive and Kit or platelet-derived growth factor receptor alpha (PDGFRA) mutation-driven mesenchymal tumors of the gastorointestinal tract. Imatinib mesylate (Glivec, Novartis Pharma, Switzerland), a selective inhibitor of BCR-ABL tyrosine kinase and Kit and PDGFRA tyrosine kinases, has become the standard therapy for advanced/metastatic GISTs worldwide.
However, following an initial response, a secondary resistance to the drug occurs at a median time of 2 years following the initiation of treatment and affects most patients after 4 years. Therefore, additional therapy including surgery is essential.
Here we report the case of a resected giant GIST of the jejunum that disseminated following treatment with imatinib, for considering multimodal therapy that combines adjuvant surgery and molecular-targeted agent.
Case report
A 59-year-old male consulted his family doctor for a 2-month history of a lower abdominal mass in July 2007.
Laboratory tests showed no abnormalities including tumor markers. Abdominal computed tomography (CT) images revealed a giant tumor, 21 9 12 9 20 cm in size, in the abdominal cavity (Fig. 1a) . Following transabdominal wall needle biopsy at the hospital, the tumor cells were strongly positive for the c-Kit oncogene, positive for actin and negative for S100 protein and CD34; thus, GIST was diagnosed. The patient was referred to a hospital in Tokyo and admitted to the hospital. Administration of 400 mg/day imatinib was initiated to confirm the diagnosis; 5 months later he was referred to Okayama University hospital. Eight months after initiating the treatment, CT showed that the tumor had considerably decreased in size, 13 9 11 9 11 cm (Fig. 1b) , but revealed multiple tumors in the small intestine and mesenterium, indicating dissemination. Administration of imatinib was continued, and the main tumor has not changed in size since that time, but the maximum standard uptake value (SUV) from 18FDG PET scans of the main tumor was less than 2.5 in May 2008. The dissemination gradually diminished thereafter and almost disappeared except for a tumor in the right upper abdomen (Fig. 2) . We deduced the effect of imatinib was a partial response, and we continued its administration.
Three years after initiating the treatment, follow-up CT demonstrated that the disseminated lesions were enlarged, and a part of the intrapelvic tumor was suspected to be viable (Fig. 3) . We concluded that the tumor had developed partial resistance to imatinib. We surgically removed the tumor, which was the size of a child's head and had developed within the jejunum approximately 20 cm at the back of Treitz' ligament, along with a small part of jejunum. In addition, several tumors 5-30 mm in size were observed throughout the intra-abdominal mesenterium and peritoneum. We surgically removed as many of these tumors as possible (Fig. 4a ), but the tumors less than 5 mm in size were abandoned.
Pathologically, most tumors showed hyalinization/ edematous change/necrosis/apoplexy lesions, and no viable tumor cells were found except those in a small part of the primary tumor, in which mitosis was 0-1/50 high power fields (HPFs) (Fig. 4b) . Immunostaining revealed that the tumor cells were positive for CD34 (Fig. 5a ), c-Kit (Fig. 5b ) and a-smooth muscle actin (SMA) (Fig. 5c) , and negative for S100 and p53. The MIB-1 index was approximately 5% (Fig. 5d ). Genetic analysis of the c-Kit mutation revealed an exon 11 c554-559 deletion (Fig. 6) . The patient continues to be recurrence-free 10 months since surgery.
Discussion
The efficacy of imatinib for the treatment of unresectable, metastatic, recurrent GIST has been established, and imatinib is considered to be the drug of choice [1, 2] . However, approximately 12-14% of GIST patients treated with imatinib, showed no effect after the initiation of treatment (primary resistance), and half of the patients who initially respond developed resistance (secondary resistance) after receiving the treatment for approximately 2 years. Thus, cases of radical cure are extremely rare [3] . In addition, continuous administration may be impossible in some patients because of adverse effects.
Two paths of action can be considered for imatinibresistant GIST: (1) increased dosage of imatinib, and (2) change to sunitinib. However, sunitinib tends to be ineffective on exon 17 or 18, which is the activation loop domain, and its efficacy in the treatment of imatinibresistant GIST shows a clinical benefit response (CBR) of 53% and an intermediate PFS value of approximately 34 weeks [4] , which make it inefficient. We believe that resectable partially resistant GIST should be surgically resected to preserve sunitinib as a future alternative. The 2009 National Comprehensive Cancer Network (NCCN) guidelines state that, if unresectable, metastatic, recurrent GIST can be controlled by administration of imatinib, surgical intervention should be considered at an appropriate time. Bauer et al. also reported that if administration of imatinib can control unresectable, metastatic GIST, surgical intervention tends to extend the survival period to a greater degree than continued therapy with solely imatinib [5] . At the American Society of Clinical Oncology (ASCO) in 2010, Nguyen et al. reported a better prognosis for patients whose metastatic GIST was, in principle, treated with imatinib followed by surgical intervention. According to Nguyen et al., the median survival rate of patients treated solely with imatinib was 4.3 years, while it was significantly improved to 8.1 years in patients treated with imatinib combined with surgical intervention. Furthermore, a randomized comparison study (EORTC 62063) is currently being conducted in Europe and Australia to review the utility of surgical intervention in patients with metastatic, recurrent GIST controlled by imatinib therapy. With regard to the timing of surgical intervention, a retrospective study by Mussi et al. [6] in unresectable, recurrent, metastatic, GIST patients treated with imatinib revealed that surgery performed when the best clinical response was obtained yielded a significantly better 2-year-progressionfree survival (PFS) and 5-year-disease-specific survival (DSS) than surgery conducted when local progression had already been diagnosed. A single-facility retrospective study of patients with unresectable, metastatic GIST conducted in the USA showed a significantly better prognosis when resection of the residual tumor was performed under the control of tyrosine kinase inhibitory agents, such as imatinib, compared with surgical intervention at an aggravated stage [7] . In other words, if surgical resection is performed on the GIST during the efficacious stage when imatinib resistance emerges or in the early stages of partial resistance, an excellent prognosis may be obtained, such as in the patient described here. Thus, the efficacy of imatinib in the treatment of GIST and the early discovery of resistance are considered to be important factors in its prognosis. Generally, the efficacy of treatment of a solid tumor is assessed on the basis of RECIST criteria, and more than 30% reduction in tumor diameter is judged to be a partial response. However, a change in CT value in GIST due to reduced blood flow or cystic changes of the tumor is known to reflect a treatment effect. Therefore, to evaluate the efficacy of imatinib in the treatment of GIST, the Choi criteria that include tumor diameter and changes in CT value have been used [8] . Furthermore, 18FDG-PET enables the evaluation of viable cells in GIST by identifying metabolic changes in the tumors. Stroobants et al. [9] . and Antoch et al. [10] reported that, after the administration of imatinib, changes in uptake in PET are a good reflection of a treatment effect and are well correlated with prognosis in GIST. In our patient, reduction in tumor diameter stopped 8 months after the onset of administration of imatinib; however, the SUV value was as low as 2.5. Therefore, administration of imatinib was continued, and a reduction in disseminated lesion was observed for 3 years. Furthermore, Gayed et al. [11] reported that PET-CT was useful in assessment of the effect of imatinib on recurrent GIST; therefore, PET-CT is believed to be valuable in the early evaluation of resistance to imatinib in unresectable, metastatic, recurrent GIST.
Unresectable, metastatic, recurrent GIST is primarily treated with molecular-targeted therapeutic agents, such as imatinib, and adjuvant surgery, if the tumor becomes resectable, is one of the most effective therapeutic strategies. Even when partial resistance to imatinib is observed, combined modality therapy that involves surgical intervention is expected to improve the treatment outcome.
